Maria Magdalene Namaganda
Biographic Data
| ID | 9072190 |
|---|---|
| NAME | Maria Magdalene Namaganda |
| GIVEN NAMES | Maria Magdalene |
| FAMILY NAME | Namaganda |
| SIGNATURE | NAMAGANDA M M |
| AFFILIATIONS | University of California, San Francisco |
| ORCID | 0000-0003-1913-5506 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2026 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Durable viral suppression in the dolutegravir era
Despite widespread rollout of dolutegravir-based (DTG) antiretroviral therapy (ART) in East Africa, viral non-suppression, advanced HIV disease (AHD), and multimorbidity persist, reflecting gaps in service response rather than regimen potency alone. In Uganda’s The AIDS Support Organization (TASO) routine-care cohort (2014–2024; n = 54,348 people living with HIV), integrase inhibitor uptake is near universal, yet AHD remains common, and tuberculo…
Decade-long antiretroviral therapy in Uganda
The scale-up of antiretroviral therapy (ART) has transformed the HIV epidemic in sub-Saharan Africa, yet longitudinal public health insights from national programmatic cohorts remain scarce. As global targets move toward epidemic control and elimination of virological failure, understanding how profiles and outcomes of people living with HIV (PLWH) evolve in real-world settings is essential. The AIDS Support Organisation (TASO), Uganda’s largest …
No prominent works on this page.
Durable viral suppression in the dolutegravir era
Despite widespread rollout of dolutegravir-based (DTG) antiretroviral therapy (ART) in East Africa, viral non-suppression, advanced HIV disease (AHD), and multimorbidity persist, reflecting gaps in service response rather than regimen potency alone. In Uganda’s The AIDS Support Organization (TASO) routine-care cohort (2014–2024; n = 54,348 people living with HIV), integrase inhibitor uptake is near universal, yet AHD remains common, and tuberculo…
Decade-long antiretroviral therapy in Uganda
The scale-up of antiretroviral therapy (ART) has transformed the HIV epidemic in sub-Saharan Africa, yet longitudinal public health insights from national programmatic cohorts remain scarce. As global targets move toward epidemic control and elimination of virological failure, understanding how profiles and outcomes of people living with HIV (PLWH) evolve in real-world settings is essential. The AIDS Support Organisation (TASO), Uganda’s largest …
Cohort (2 works) · HIV-related health complications and treatments (2 works) · HIV/AIDS drug development and treatment (2 works) · HIV/AIDS Research and Interventions (2 works) · Socioeconomic status (2 works) · Antiretroviral therapy (1 work) · Comorbidity (1 work) · Descriptive statistics (1 work) · Disease (1 work) · Dolutegravir (1 work)